Epizyme (EPZM) Downgraded to Sell at ValuEngine

Epizyme (NASDAQ:EPZM) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Thursday.

Other equities analysts have also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective (down previously from $26.00) on shares of Epizyme in a research report on Wednesday, March 14th. SunTrust Banks reissued a “buy” rating and issued a $27.00 price target on shares of Epizyme in a research report on Wednesday, March 14th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Epizyme in a research report on Monday, May 21st. Roth Capital set a $24.00 price target on shares of Epizyme and gave the company a “buy” rating in a research report on Tuesday, April 24th. Finally, Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research report on Thursday, March 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $23.00.

Shares of Epizyme traded down $0.35, reaching $13.25, during mid-day trading on Thursday, Marketbeat reports. 438,900 shares of the company were exchanged, compared to its average volume of 451,062. The stock has a market capitalization of $1.00 billion, a P/E ratio of -6.08 and a beta of 2.09. Epizyme has a 1 year low of $11.15 and a 1 year high of $21.40.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.05. During the same quarter in the previous year, the firm posted ($0.56) EPS. equities analysts predict that Epizyme will post -2.22 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of EPZM. Schwab Charles Investment Management Inc. boosted its position in Epizyme by 13.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 245,756 shares of the biopharmaceutical company’s stock valued at $3,085,000 after buying an additional 28,588 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Epizyme in the 4th quarter valued at $202,000. The Manufacturers Life Insurance Company raised its holdings in shares of Epizyme by 18.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 38,451 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 6,005 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Epizyme by 5.3% in the 4th quarter. Bank of New York Mellon Corp now owns 212,983 shares of the biopharmaceutical company’s stock valued at $2,672,000 after purchasing an additional 10,805 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Epizyme by 17.1% in the 4th quarter. BlackRock Inc. now owns 3,965,391 shares of the biopharmaceutical company’s stock valued at $49,766,000 after purchasing an additional 579,662 shares in the last quarter. 85.22% of the stock is owned by institutional investors.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply